Skip to content

Clinical trial of tocilizumab for skin fobrosis in systemic sclerosis

Clinical trial of tocilizumab for skin fobrosis in systemic sclerosis - Clinical trial of tocilizumab for skin fobrosis in systemic sclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012214
Enrollment
5
Registered
2013-11-05
Start date
2013-11-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic sclerosis

Interventions

Sponsors

The University of Tokyo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients with systemic sclerosis with sever skin sclerosis 2)Over 6 modified Rodnan total skin score with skin sclerosis on fingers, dorsal hands, forearms, and upper arms; change of total skin score is within 20% during the screening period (two months) 3)no malignancy 4)from 20 years old to 80 years old 5)Agreement to contraception during the study period 6)Patients who are able to give consent in writing after reading the explanatory text

Exclusion criteria

Exclusion criteria: 1)during treatment with equal drug 2)previous history of anaphylactic reactions to this drug 3)significant infection 4)significant liver damage 5)significant renal damage 6)pregnancy 7)breast-feeding 8)participating in other clinical trial within three months before the beginni ng of this trial 9)judged inappropriate for this study by the physicians

Design outcomes

Primary

MeasureTime frame
Sum of skin scores from 17 sites of the body (modified Rodnan total skin score)

Countries

Japan

Contacts

Public ContactAyumi Yoshizaki

The University of Tokyo Department of Dermatology, Faculty of Medicine, Graduate School of Medicine

yoshizakiay-der@h.u-tokyo.ac.jp03-5800-8661

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026